KitL, via its receptor cKit, supports primordial germ cell (PGC) growth, survival, migration and reprogramming to pluripotent embryonic germ cells (EGCs). However, the signaling downstream of KitL and its regulation in PGCs remain unclear. A constitutively activating mutation, cKit V558D , causes gain-of-function phenotypes in mast cells and intestines, and gastrointestinal stromal tumors (GISTs) when heterozygous. Unexpectedly, we find that PGC growth is not significantly affected in cKit V558D heterozygotes, whereas in homozygotes, increased apoptosis and inefficient migration lead to the depletion of PGCs. Through genetic studies, we reveal that this oncogenic cKit allele exhibits loss-of-function behavior in PGCs distinct from that in GIST development. Examination of downstream signaling in GISTs from cKit V558D/1 mice confirmed hyperphosphorylation of AKT and ERK, but both remain unperturbed in cKit V558D/1 PGCs and EGCs. In contrast, we find reduced activation of ERK1/2 and JNK1 in cKit V558D homozygous PGCs and EGCs. Inhibiting JNK, though not ERK1/2, increased apoptosis of wild-type PGCs, but did not further affect the already elevated apoptosis of cKit V558D /V558D PGCs. These results demonstrate a cell-context-dependent response to the cKit V558D mutation. We propose that AKT overload protection and JNK-mediated survival comprise PGC-specific mechanisms for regulating cKit signaling.
INTRODUCTION
Primordial germ cells (PGCs) are the embryonic founders of the adult gametes. In most animals, PGCs are set aside as a distinct cell lineage during early embryogenesis. Mammalian PGCs are specified from the epiblast at E7.25 in mice and traverse many tissues before eventually colonizing the gonad at E11.5 (1) . During their migration, PGCs undergo proliferation, increasing from approximately 100 at E8. 5 to approximately 3000 at E11.5 and continue to divide in the genital ridges, where they differentiate along male-or female-specific gametogenesis programs (2) . PGCs are also the source of pluripotent stem cells called embryonic germ cells (EGCs) that resemble embryonic stem cells (ESCs) in their properties and gene expression (3, 4) . cKit and its ligand (KitL), encoded by W and Steel loci, respectively, are essential for PGC survival, migration and proliferation in mice. Loss-of-function cKit mutations result in the failure of PGC proliferation after E8.5, impaired migration and a large proportion of ectopic PGCs (5, 6) . Dynamic regulation of KitL expression in somatic cells promotes the survival of properly localized PGCs and the apoptosis of ectopic PGCs (7, 8) . In vitro culture experiments demonstrate that soluble KitL [or stem cell factor (SCF)] is required in a dose-dependent manner for PGC survival (9) , proliferation (10) and migration (11, 12) . On the other hand, cKit gain-of-function mutations are typically oncogenic (13, 14) . A frequent mutation in the second kinase domain, at Valine 816, is associated with testicular germ cell tumors, but may promote their progression rather than initiation (15) (16) (17) . Activating mutations in the cKit juxtamembrane (JM) domain are found in human gastrointestinal stromal tumors (GISTs), and a mouse model of the most frequently mutated residue, V558 (V559 in human), replicates the disease (14, 18, 19) ; these mutations presumably disrupt JM-mediated inhibition of cKit autophosphorylation in the absence of KitL (20) . Tyrosine phosphorylation, accelerated by KitL-induced receptor dimerization, provides docking sites for mediators of several * To whom correspondence should be addressed. Tel: +1 4154765471; Fax: +1 4155027866; Email: lairdd@stemcell.ucsf.edu # The Author 2012. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com signaling pathways: PI3K/AKT, MAPK, JAK-STAT and Src (21) (22) (23) (24) (25) . The functions of these respective pathways in PGCs remain largely opaque. The absence of PGC phenotypes in mouse models with deletions of the tyrosine docking residues for PI3K (Tyr719) and Src (Tyr 567/569) present a conundrum for understanding these important pathways in this rare and relatively inaccessible cell type (26) (27) (28) .
Here, we used an activating mutation, cKit
V558D
, to ascertain the in vivo consequences of cKit pathway overstimulation for PGCs. Through genetic and biochemical studies, we found that the cKit V558D mutation does not significantly affect PGC growth in heterozygotes and causes unexpected PGC depletion and loss of MAPK signaling in homozygotes. Our results suggest that the signaling requirements of PGCs are distinct from GISTS and furthermore uncover JNK as an important effector of cKit-mediated PGC survival.
RESULTS
A constitutively activating cKit mutation, V558D, does not disrupt PGC development in heterozygotes, but causes PGC depletion in homozygotes
To investigate the consequence of cKIT over-activation for PGC development, we examined a mouse mutant with a targeted deletion of Valine 558 (cKit V558D ), a residue in the JM domain (18) . Gain-of-function phenotypes in diverse tissues have been described in cKit V558D heterozygotes: a 4-fold increase in mast cell number, increase in skin melanocytes and 100% penetrant GIST [P. Besmer, personal communication (18) ]. In contrast to these phenotypes, testes and ovaries of cKit V558D/+ appeared grossly normal in size, weight and morphology, and testicular tumors were not detected in adult mice by the time of their mortality at 3 -6 months of age from GISTs (n ¼ 10) (Supplementary Material, Fig. S4 ). In E17.5 cKit V558D/V558D fetal testes, we did not observe any Nanog and E-cadherin-expressing neoplasias (Supplementary Material, Fig. S1A ) as has been described on genetic backgrounds conducive to teratomas (29) .
Upon examining mid-gestation embryos, we observed an unexpected PGC phenotype. By E11.5, as PGCs aggregate and colonize the gonads, a marked depletion was observed in cKit V558D/V558D by whole-mount immunostaining for the PGC marker GCNA (Fig. 1A) . Quantitative image analysis of E11.5 gonads (12) revealed a corresponding decrease in PGCs of homozygotes (mean 371 + 76 PGCs) compared with WT (1909 + 549) or cKit V558D/+ (1142 + 270) littermates (P , 0.05, Fig. 1B ). Although cKIT protein is detectable in PGCs as early as E7.75 (30, 31) and cKit loss-of-function mutants exhibit measurable PGC loss by E9.0 (5), we did not observe earlier phenotypes in cKit V558D homozygotes. At E8.0-8.5, alkaline phosphatase (AP) staining revealed normal PGC incorporation into the hindgut and comparable PGC numbers between WT and cKit V558D/V558D embryos (Fig. 1C) , suggesting that PGC specification occurs normally in these mutants. Interestingly, cKit V558D/+ embryos show a slight and transient increase in PGC numbers at E8.0-8.5 (Fig. 1C) , whereas no differences in PGC numbers could be detected near the end of PGC migration at E10.5 (Fig. 1A) .
The observed deficit of PGCs in cKit V558D/V558D mutants could arise by altered rates of apoptosis, proliferation or migration, and cKit has been implicated in all of these cellular mechanisms (5, 9) . In E11.5 histologic sections, we found a 3.0-fold increase in the frequency of SSEA1 + PGCs expressing the apoptotic marker cPARP in cKit V558D/V558D gonads (1.74 + 0.23%) compared with either WT or heterozygotes (0.59 + 0.17 and 0.69 + 0.16%, respectively), as shown in Figure 1D . Examining proliferation by 5-ethynyl-2 ′ -deoxyuridine (EdU) incorporation and phospho-histone H3, we observed no significant differences between the three genotypes ( Fig. 1E and data not shown) . Finally, we quantified the efficiency of PGC migration at E11.5, after the majority of PGCs have colonized the gonads. In serial sections, we observed increased accumulation of PGCs in the dorsal mesentery (7.99 + 3.17% of the total number) of cKit V558D/V558D compared with WT embryos (1.02 + 0.99%, Fig. 1F ). Taken together, these results indicate that PGC depletion of cKit V558D/V558D embryos is due to increased apoptosis and aberrant migration. In support of this conclusion, we observed in double-mutant analysis that the V558D phenotype was partially rescued by genetic removal of the pro-apoptotic gene Bax ;Bax 2/2 embryos was increased over cKit V558D/V558D at E11.5. However, the number of ectopic PGCs also increased in double mutants, similar to the previous cross between a null allele for KitL and Bax (7, 32) .
We compared the unexpected PGC phenotype of cKit V558D/V558D embryos with that of loss of function alleles of cKit. In a genome-wide recessive ethylnitrosourea (ENU) mutagenesis screen for PGC defects, we identified such a novel allele, cKit S830R (33) . Sequencing revealed an A C change at Chr5: 76 048 608 (NCBI37/mm9) that produces a substitution of serine 830 by arginine in the second kinase domain of the predicted protein (Supplementary Material, Fig. S3 ). cKit S830R/+ mice were characterized by white spots on their belly and back ( Fig. 3A and Supplementary Material, Fig. S3 ) similar to the pigment defects in the null allele cKit W (6). Most cKit S830R/S830R mice died perinatally, and the few escapers that survived to adulthood were black-eyed, albino and failed to breed (Supplementary Material, Fig. S3 ). As early as E8.0 (4-6 somite stages), a deficit in the number of PGCs in cKit S830R/S830R mutants could be detected by AP staining; whereas 50-80 PGCs were present in wild-type, cKit S830R homozygotes possessed 20-50 (P , 0.001; Fig. 2A ). Furthermore, cKit S830R mutant PGCs tended to adhere together in clumps at the base of allantois at this stage, reminiscent of KitL Sl/Sl mutants (32), whereas they have already incorporated into the endoderm pocket in wild-type and cKit S830R/+ littermates (data not shown). By the 9-12 somite stage, whereas PGCs in WT embryos increase rapidly ( 90-110), the number in cKit S830R/S830R embryos remained around 40, and did not rise at E10.5 (25 + 3.2 compared with 816 + 68 in wild-type) or by E11.5 (6 + 0.8 compared with 2414 + 176 in wild-type, Fig. 2B , C and E). PGC depletion in these mutants is at least partially due to excessive apoptosis, as the loss of one Bax allele slightly increased cKit S830R/S830R PGC number to 45.5 + 5.3 (P , 0.001) and the loss of two Bax alleles significantly increased cKit S830R/S830R PGC number from 10 + 3.9 to 130 + 6.4 at E10.5 (P , 0.001; Fig. 2D ). (Fig. 3A) . Compound heterozygotes were viable, and their germ cell deficiency persisted; by 12 weeks after birth, the gonads were very small, with testes seminiferous tubes sparsely populated or devoid of sperm, and cKit V558D/S830R ovaries containing mainly luteinized interstitial cells and few immature and unhealthy ;KitL Sl/Sl double homozygotes (Fig. 3C ), suggesting that cKit V558D/V558D does not have ligand-independent activity in PGCs. Interestingly, on a KitL Sl/Sl null background, cKit V558D/+ significantly increases the mean PGC number from 18 to 63 (Fig. 3C) , demonstrating a functional consequence for ligand-independent activity in promoting PGC survival. Together, these compound mutants suggest that cKit V558D is responsive to and dependent upon KitL, as its genetic ablation significantly impacts PGC phenotypes; furthermore, cKit V558D exhibits no basal or ligand-independent activity in PGCs when homozygous, and when heterozygous, is capable of low levels of autoactivity.
In three different genetic contexts, homozygous V558D behaves as a loss-of-function rather than a gain-of-function allele in PGCs. However, one allele of V558D appears to be sufficient for the development of GISTs on any genetic background; masses were observed in the cecum of 100% of cKit V558D/S830R , cKit V558D/W and cKit V558D/+ ;KitL Sl/+ adults at ages of 8 -12 weeks (Fig. 3D) . Whereas GIST development appears to be unaffected by reduced dosage of KitL, reduced levels of cKit or homodimerization of V558D, PGC development is highly compromised. Collectively, these phenotypes reveal distinct and cell-context-specific cKit signaling requirements between GISTs and PGCs. Fig. S5 ). By annexin V staining, we observed an increase in apoptosis among cKit V558D/V558D EGCs (5.43 + 1.73%) compared with heterozygous (2.36 + 0.37%) or wildtype EGCs (2.14 + 0.01%; Fig. 4B ). This decrease in the survival of cKit V558D/V558D EGCs compared with heterozygote or wild-type EGCs paralleled the trend observed in PGCs (Fig. 1D) . We confirmed that all three EGC lines express similar levels of cKit transcript (Fig. 4C ) as well as total cKIT protein ( Fig. 4D) , eliminating the possibility of variability due to cKit expression levels.
We next assessed cell-surface expression of cKIT in mutants, since activity-induced endocytosis is a well-known negative feedback mechanism for cKit (37) . Flow cytometric comparison of cKIT expression at the cell surface revealed a moderate reduction in cKit V558D/+ EGCs and even greater reduction in cKit V558D/V558D EGCs (Fig. 4E) . We wondered whether progressively reduced surface cKIT in V558D heterozygous and homozygous EGCs reflects increased receptor autoactivity, and furthermore whether this attenuation mechanism affects subsequent ligand sensitivity. To assay the ligand responsiveness of each EGC genotype, we pulsed with 60 ng/ml soluble KitL (SCF); a corresponding decrease in cKIT surface expression was observed after 30 min of SCF treatment, and this relative decrease was identical in wild-type, cKit V558D/+ and cKit V558D/V558D EGCs despite the initially different levels (Fig. 4F) . We sought to validate these discrepancies in EGC cKIT expression in vivo, and similarly found in E11.5 PGCs that the down-regulation in cKit V558D/+ and further in cKit V558D/V558D was comparable with that in EGCs (Fig. 4G) . In contrast, we observed that cKit S830R/+ PGCs exhibit wild-type levels of cKIT protein on cell surface (Fig. 4H ), suggesting differences in mutant receptor signaling or trafficking between cKit V558D and cKit
S830R
. These results establish the use of EGCs as a relevant tool for studying V558D mutant receptor activity; together with the cKit 
demise of PGCs. These genetic studies suggest that PGC loss in V558D homozygotes occurs by a different, loss-of-function mechanism. We next used the EGCs to interrogate phosphorylation of candidate downstream signaling molecules biochemically. Hyperphosphorylation of AKT was previously reported in GISTs from cKit V558D/+ mice, and markedly decreased following imatinib-induced tumor regression (38) . We first compared AKT phosphorylation between EGCs derived from WT PGCs and GISTs isolated from cKit V558D/+ mice by western blot (Fig. 5A) . Consistent with previous studies (38), we observed a high level of AKT protein expression and phosphorylation in GIST tumor lysates relative to wild-type EGCs. Upon comparing AKT phosphorylation in WT and cKit V558D EGCs, we observed uniform levels among all genotypes in the absence of added SCF, and similar P-AKT increases following SCF stimulation (Fig. 5B) . In E11.5 sections, we Human
detected robust P-AKT immunoreactivity in the nuclei of approximately half of PGCs (Fig. 5C) ; cytoplasmic P-AKT was not observed in PGCs, but was present in other somatic cells. However, the frequency of P-AKT-positive PGCs did not differ between wild-type, heterozygotes and homozygotes (Fig. 5D ). This result suggests, first, that altered AKT signaling does not underlie the loss of PGCs in cKit V558D/V558D
, and, second, that cKit V558D/+ does not elevate AKT activity in PGCs as in GISTs, and presumably their precursors (38) .
We also examined several effectors of the JAK-STAT pathway, of which only P-STAT-3 could be detected in EGCs. As shown in Supplementary Material, Figure S6 , we observed a moderate increase of STAT-3 phosphorylation in cKit V558D/+ , but no alteration in cKit V558D/V558D EGCs.
Loss of MAPK signaling compromises the survival of cKit V558D/V558D mutant PGCs
We next examined effectors of the MAPK pathway in EGCs and PGCs. By immunoblotting, we confirmed that ERK was consistently more activated in GISTs from cKit V558D/+ mice compared with EGCs (Fig. 6A) . ERK phosphorylation was similar between wild-type and cKit V558D/+ EGCs in the absence of exogenous SCF, whereas phosphorylation was markedly reduced in cKit V558D/V558D EGCs (Fig. 6B ). This persistence of ERK1/2 activity may be attributable to autocrine SCF production by EGCs, which we noted by qRT-PCR (data not shown). Following SCF addition, ERK1/2 phosphorylation increased modestly in cKit V558D/V558D EGCs, but remained significantly lower than that of wild-type or heterozygote. We sought to validate these ERK phosphorylation differences in PGCs by immunohistochemistry. In E11.5 sections, P-ERK1/2 was primarily detected in cytoplasm and occasionally in the nucleus of PGCs within the gonad, in 56.4% of wild-type PGCs ( Fig. 6C and D) , consistent with a previous report (39) . cKit V558D/+ PGCs did not differ from wildtype in ERK phosphorylation. However, in cKit V558D/V558D , P-ERK1/2 immunoreactivity was much weaker and could be scored in only 36.7% of PGCs (Fig. 6C and D) ; this result in vivo corroborates the P-ERK1/2 loss observed in cKit V558D/V558D EGCs. We tested the effect of P-ERK1/2 loss by culturing wild-type E11.5 PGCs in an MEK inhibitor, PD0325901. However, at a range of doses, programmed cell death was not increased in either PGCs co-cultured with somatic cells (Fig. 6E ) or purified PGCs (data not shown); these studies could suggest that cKIT-mediated ERK1/2 signaling is not critical for PGC survival.
We next examined the activity of JNK, another important MAPK that mediates mast cell proliferation via SCF (40) . In EGCs, phosphorylation of JNK1 was diminished in cKit V558D/V558D compared with that in wild-type or heterozygote (Fig. 7A) . Examination of GISTs from cKit V558D/+ mice revealed, in contrast, undetectable levels of JNK phosphorylation compared with EGCs (Fig. 7B) . By immunofluorescence, we were able to detect phosphorylated JNK in E11.5 cultured PGCs. Whereas a punctate nuclear signal was observed in wild-type and heterozygotes, the intensity of P-JNK was significantly reduced in cKit V558D/V558D PGCs; quantitation of this signal in confocal stacks corroborated a highly significant reduction of P-JNK in homozygous PGCs and a possible decrease in heterozygotes (Fig. 7C) . Since JNK has not been previously implicated in PGC development, we began with an assay of its function in E11.5 PGCs co-cultured with somatic cells and exogenous SCF. Addition of a JNK inhibitor (JNKi), SP600125, significantly increased apoptosis in a dose-dependent fashion (Fig. 7D) . Primary PGCs purified from E11.5 WT embryos responded similarly to the JNKi (data not shown), suggesting that JNK acts autonomously in PGCs to promote their survival. cKit V558D/V558D Figure 6 . Hypophosphorylation of ERK1/2 in cKit V558D/V558D PGCs and EGCs. (A) GISTs (from three cKit V558D/+ mice) and cell lysates isolated from sorted EGCs (WT, two lines) were immunoblotted for P-ERK1/2, total ERK1/2 and b-tubulin, revealing high levels of activated ERK in GISTs. (B) EGCs sorted from STO cells were starved for 2 h and then treated with 50 ng/ml SCF for 10 min. Immunoblotting revealed a decrease in ERK1/2 phosphorylation in cKit V558D/V558D
. The P-ERK1/2 levels shown on the graphs have been normalized to total ERK1/2. (C) WT, cKit V558D/+ and cKit V558D/V558D embryos at E11.5 were sectioned and co-immunostained for P-ERK1/2 and Stella, a PGC marker. P-ERK1/2 (red), mainly detected in cytoplasm and occasionally in the nucleus, was strong (white arrow heads) in WT and heterozygous PGCs, whereas it was weak or absent (yellow arrow heads) in cKit V558D/V558D PGCs. Frequencies of P-ERK1/ 2-positive PGCs (exhibiting strong staining) were quantified (D). (E) PGC from E11.5 WT embryos were co-cultured with somatic gonad cells in DMEM with 50 ng/ml SCF and an MEK inhibitor, PD032590, at the indicated concentrations for 20 h. The frequency of apoptotic PGCs, detected by caspase-3 and SSEA1 co-immunostaining, did not increase with MEK inhibitor treatment. Scale bars ¼ 5 mm.
* P , 0.05, * * * P , 0.001.
PGCs cultured without JNKi exhibited similarly elevated levels of apoptosis. Importantly, the addition of JNKi did not further increase apoptosis of cKit V558D/V558D PGCs in culture (Fig. 7E) .
Together, our data raise the possibility that cKit-mediated JNK signaling promotes PGC survival but acts independently of ERK1/2. These results demonstrate the suppression of two MAPK effectors in cKit V558D/V558D EGCs as well as PGCs and show that pharmacologic inhibition of JNK induces PGC apoptosis. The pronounced difference between the phosphorylation state of both ERK and JNK in EGCs and GISTs underscores the distinct and cell-context-specific cKit signaling requirements suggested by our genetic experiments.
DISCUSSION
KitL-cKit is the most critical growth factor signaling pathway for mammalian PGCs, as its disruption produces the most severe effects on PGC survival. In this report, we used an oncogenic cKit gain-of-function mutation, V558D, to study the consequences of overactivated cKit for PGC development. Contrary to phenotypes in mast cells and intestine, we find that cKit V558D does not cause PGC overgrowth; whereas GISTs arising in heterozygotes have been associated with hyperactive AKT and ERK signaling (18, 38, 41) , normal levels found in EGCs and PGCs argue for the existence of mechanisms that buffer cKit signaling. Surprisingly, V558D homozygosity leads to apoptotic attrition of PGCs and EGCs and the attenuation of MAPK signaling. Our work suggests that loss of JNK underlies PGC death in cKit V558D/V558D and that JNK is a previously unrecognized mediator of PGC survival via cKit. Together, these results underscore the distinct and cell-context-specific management of the KitL-cKit signaling pathway.
First and foremost, this work reveals unusual behavior of an oncogenic, autoactivating allele in PGCs. cKit V558D has been established as a gain-of-function mutation in mast cells and interstitial cells of Cajal, where it produces hyperproliferation or hyperplasia (18, 38, 42) . Contrary to expectation, our analysis in PGCs revealed loss-of-function behavior of this mutant: when homozygous and in trans with two cKit loss-of-function alleles, cKit S830R and cKit
caused a reduction in PGCs by E11.5, whereas GISTs still formed. Similar cell-context-dependent properties of cKit signaling have been described for a number of other alleles (28, 43) . Examination of cKit V558D phenotypes in the KitL null genetic background, in which ligand is absent, supports the notion that cKit V558D lacks autoactivity in PGCs when homozygous, as the double mutants phenocopy the virtual absence of PGCs in KitL single mutants. However, the partial rescue of KitL Sl/Sl PGCs by one V558D allele indicates a different phenomenon in the heterozygote. This result could suggest that cKit V558D autoactivity in PGCs requires the presence of a wild-type cKit allele. On balance, the cKit V558D/+ -mediated PGC increase is significant in a KitL Sl/Sl background, but corresponds in numbers to 6% of the total PGC population in wild-type at E10.5; a 6% increase in PGCs would not be detected in heterozygotes, which are indistinguishable from wild-type.
Alternatively, this demonstrated ligand-independent activity in KitL Sl/Sl ;cKit V558D/+ mutant PGCs could suggest the presence of a molecular overload protector in PGCs that restricts the level of cKit signaling above a threshold. In this case, the persistence of normal PGC development in cKit V558D/+ could result from such buffering mechanisms, which are not in effect at low levels of cKit signaling, such as on the Sl/Sl background.
Examination of the downstream signaling mediators in EGCs and PGCs corroborates the phenotypes observed in V558D heterozygotes and homozygotes. Previous biochemical studies of V558D focused on GISTs, cultured bonemarrow-derived mast cells or overexpression in cell lines, but signaling has not been examined in normal tissues (18, 38, 41) . cKit V558D/+ EGCs exhibited levels of AKT and ERK1/2 phosphorylation comparable with wild-type. Although STAT3 phosphorylation was elevated, this apparently does not affect rates of proliferation and apoptosis in cKit V558D/+ EGCs, which were identical to wild-type. Many studies of GISTs, including the cKit V558D/+ mouse model, point to active AKT and ERK pathways as critical for tumor growth (18, 38, 41, 44, 45) . Therefore, the unaltered levels of both mediators in cKit V558D/+ EGCs is striking, particularly in comparison with the high AKT and ERK phosphorylation in GISTs. In PGCs, AKT phosphorylation occurs rapidly upon the addition of SCF (11) and has been associated with survival and cell-cycle regulation (46) (47) (48) (49) . However, our direct in vivo examination of phospho-AKT in PGCs confirmed that the levels of response remain unaffected by V558D. The discrepancy between AKT activation in cKit V558D/+ GISTs and EGCs/PGCs reinforces the idea of a germ-cell-specific mechanism for attenuating high levels of PI3K signaling. Perhaps consistent with this notion, in vivo PGC development was not disrupted in a mouse engineered for increased AKT activation that had activity even in the absence of tamoxifen (47) . The basis of this proposed buffering mechanism in PGCs, or its loss in tumor cells, will be important future questions.
The state of signaling in cKit V558D/V558D EGCs and PGCs sharply diverged from that in heterozygotes. As might be predicted by the loss-of-function phenotypes, V558D homozygotes exhibited reduced phosphorylation of the MAP kinases ERK1/2 and JNK1 compared with either wild-type or heterozygotes. Although it may be tempting to speculate that reduced cKIT cell-surface expression in homozygotes contributes to this signaling deficiency, this relationship is unclear, as cKit alleles with aberrant trafficking can contribute to signaling from within subcellular compartments (50, 51) . MAP kinase signaling remains largely unstudied in PGCs. Work in a fibroblast growth factor receptor 1 mutant demonstrated a reduction in both PGC survival and ERK1/2 activation, but did not establish a causal connection (39) . Despite the observed loss of ERK1/2 phosphorylation in EGCs and PGCs in vivo, 20 h culture of PGCs with an MEK inhibitor did not recapitulate the PGC apoptosis phenotype of cKit V558D/V558D . Although in a previous report MEK inhibitor diminished PGC numbers after 7 days in culture, by this point the remaining cells likely underwent transformation to EGC colonies, which may respond differently (48) . Our studies diminish the possibility that ERK signaling promotes PGC survival in the E11.5 gonads within the observed time frame. However, ERK likely mediates other functions of PGCs downstream of cKit, such as migration, as suggested by in vitro studies with the MEK inhibitor (11) . Alternatively, recent demonstration that ERK inhibition preserves the naïve pluripotent state and enhances EGC derivation suggests, tantalizingly, that cKit-mediated ERK signaling promotes differentiation of PGCs in the gonad (52) .
Our studies of cKit V558D/V558D more clearly implicate another MAP kinase, JNK, in promoting PGC survival via cKit. Numerous studies paradoxically link the JNK pathway to both activation and avoidance of apoptosis, depending on cell type, stimulus, duration of activation and activity of other signaling pathways (53) . JNKs are highly activated by cellular stresses such as heat shock, UV and irradiation and by inflammatory cytokines including TNF-a and IL-1. On the other hand, a number of growth factors including EGF, nerve growth factor and SCF induce JNK activation (40, 54 (55) . A pro-survival function of JNK has been reported, and operates through the direct phosphorylation of the proapoptotic mediator BAD, which prevents its association with BclX (56) . The expression of BAD in migratory PGCs has been established (7) . However, the intriguing localization of phospho-JNK to the nucleus of PGCs could suggest an alternative, transcriptional role. Recent work in differentiating ESCs uncovered a novel function for JNKs as co-regulators of transcription that directly modify histones within promoter regions (57) . In contrast to PGCs and EGCs, the absence of JNK activation we observed in GISTs is consistent with previous characterization of GISTs from other genetic models (58) and further underscores the cell-context-specific behavior of cKit
V558D
. The mechanisms and other functions of this newly recognized cKit-JNK axis in PGCs as well as EGC derivation warrant further investigation.
In summary, these studies demonstrate discrete and lineagespecific functions of separate signaling pathways activated by cKit. Our results are consistent with a model in which PGCs depend upon cKit-JNK signaling for their survival and rely upon ERK for other functions. The molecular mechanisms by which these MAP kinases regulate such important functions of early germ cells remain to be elucidated. Evidence for the resistance of PGCs to high levels of cKit signaling raises the question of whether such a mechanism is protective against germ cell tumors.
MATERIALS AND METHODS

Mouse breeding, mapping and genotyping
All animal work was conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee at the University of California, San Francisco. Embryos were generated in timed matings by monitoring for copulatory plugs. cKit V558D mice (MGI:2663995), a gift from Dr P. Besmer, Sloan-Kettering Institute, were genotyped as described (18) and maintained on a mixed C57BL/6-CD1 background to extend the survival of heterozygotes beyond 3 months. Other mouse strains used included cKit W (MGI:1856232), Kitl Sl (MGI:1856161), Bax (MGI:1857429) and Oct4-DPE-EGFP (59), with genotyping performed as described elsewhere (7, 60, 61) . cKit S830R mice were identified in a recessive ENU screen at E9.5 for mouse mutants with PGC defects (12, 33) . Linkage was established with chromosome 5, using D5MIT15 and D5MIT134 SSLPs, and the cKit transcript was PCRamplified and sequenced from mutant embryo cDNA. cKit S830R mice were subsequently maintained on a C57BL/6 background and genotyped by HinP1 RFLP analysis using the following primers: 5 ′ -GAACCCCTGGACTTCTCTGCTCTT-3 ′ and 5 Fig. S3 ).
PGC ex vivo culture
The gonad-mesonephri of E11.5 embryos were dissociated with 0.25% trypsin for 3 min followed by 5 mg/ml DNase I. This cell suspension was directly seeded on chambered slides (Lab-Tek II) coated with 1 mg/ml Matrigel or else subjected to flow cytometry for PGC purification and then cultured at 378C in 5% CO 2 with DMEM/15% knockout serum replacement (KSR) (Invitrogen), 1000 U/ml LIF (Millipore) and 50 ng/ml SCF (Invitrogen) for 20 h. Cells were then fixed in 4% PFA at room temperature and immunostained for P-JNK. For MEK and JNKi experiments, PGCs collected as above or PGCs sorted from gonad-mesonephri were cultured in DMEM medium with 50 ng/ml SCF and an MEK inhibitor, PD-0325901 (Selleck and Stemgent), or a JNKi (SP600125, Calbiochem) for 20 h. Cells were fixed for immunostaining.
EGC derivation and maintenance
EGC lines were derived from E11.5 embryos as described (4, 52) . Briefly, we isolated PGCs from WT, cKit V558D/+ and cKit V558D/V558D embryos carrying Oct4-DPE-EGFP at E11.5 and cultured in DMEM/15% KSR (Invitrogen)/50 ng/ml bFGF (Sigma), 2000 U/ml LIF (EsGro)/60 ng/ml SCF (Invitrogen)/20 mM Forskolin (Sigma) and plated on Sl 4 -m220 feeders. After 7 -10 days, individual colonies were replated on STO feeders. EGC lines were maintained with STO cells in DMEM/15%KSR/LIF (1000 U/ml, EsGro).
Histology
Gonads collected from euthanized 14-week-old adults were weighed immediately. Testes were fixed in Bouin's solution overnight and ovaries were fixed in 10% neutral buffered formalin for 2 days before processing for paraffin embedding. Paraffin sections were cut serially at 5 mm and stained with hematoxylin and eosin.
Immunofluorescence staining and imaging
For whole-mount staining, embryos or gonads were fixed in methanol:dimethylsulfoxide (4:1) at 2208C, rehydrated and stained in PBS/2% non-fat milk/0.5% Tween with rocking as described (12) . Cells were fixed in 4% PFA at room temperature and immunostained. Gonads were mounted on slides in Vectashield (Vector Labs), whereas whole embryos were cleared in methyl salicylate for imaging. Frozen sections were prepared from embryos fixed for 1 h in 4% PFA, embedded and cryosectioned in OCT and blocked with 5% goat serum in PBST (PBS/0.1% Triton X-100) before immunostaining. Primary antibodies used were as follows: SSEA1 (Developmental . Alexaconjugated secondary antibodies were purchased from Invitrogen and used at 1:500. For EdU labeling, pregnant females were injected i.p. with 50 mg/g EdU (Invitrogen). Animals were euthanized after 4 h and embryos were fixed in 4% PFA and cryosectioned. EdU detection was carried out using the Click-iTTM EdU imaging kit (Invitrogen C10338). Imaging was carried out on an Olympus IX71 fluorescent microscope or on a Leica SP5 TCS microscope equipped with 405, 488, 543, 594 and 633 nm lasers. Confocal stacks were analyzed using Volocity (Improvision). The numbers of PGCs in whole-mount E10.5 embryos or E11.5 gonads were quantified as described elsewhere (12) .
Flow cytometry
Oct4-DPE-GFP + E11.5 gonad-mesonephri were dissociated in collagenase/dispase (5 mg/ml, Roche) and DNase I (1 mg/ ml, Roche) for 10 min at 378C, washed in staining medium (DMEM without phenol red + 2% FBS + 10 mM EDTA) with 1 mg/ml Sytox Blue viability stain (Invitrogen, S34857) and analyzed on a BD LSR II utilizing the 450/50 (Sytox Blue), 525/50 (GFP) and 660/20 (PE/Cy5) bandpass filters. For cKit surface staining, cells were stimulated with 60 ng/ml SCF for 20 min at 378C, washed and stained with a cKit antibody conjugated to PE/Cy5 (clone 2B8, Abcam, ab81601) for 30 min on ice. EGCs were dissociated with 0.25% trypsin for 5 min at 378C, and stained as above. Apoptosis was assessed by staining for extracellular phosphatidylserine, using annexin V-allophycocyanin (Invitrogen, A35110), according to the manufacturer's instructions. Sytox Blue was used to discriminate live cells (450/50), and APC was detected with the 660/20 bandpass filter. For proliferation assays, EGCs grown on STO feeder cells were pulsed for 1 h with BrdU (3 mg/ml), then trypsinized and fixed with 4% PFA for 15 min. After washing, antigen retrieval was performed with 2 M HCl for 20 min and neutralized with 0.1 M borate buffer (pH 8.5), permeabilized with 0.3% Triton-X-100 in PBS for 15 min at 258C and stained with Alexa 594 conjugate-BrdU antibody (1:50, Invitrogen, 03-3940) and DAPI (4 mg/ml) for 30 min.
Expression studies
For gene expression studies, RNA was extracted using TRIzol or the RNeasy kit (Qiagen), reverse-transcribed using QScript cDNA SuperMix (Quanta Biosystems, 95048 -100) and subjected to quantitative PCR for cKit at 50-100 cells/tube in SYBR Green using the following primers: CAGTCGTG-CATTTCCTTTGAC and TTCCTCGCCTCCAAGAATTG. For western blotting, EGCs sorted from STO cells were starved in DMEM for 2 h and then stimulated with 50 ng/ml SCF for 10 min before lysis in RIPA buffer containing 1% NP-40, 0.25% deoxycholate acid, 150 mM NaCl, 0.1% SDS, 50 mM HEPES (pH 7.4), proteinase and phosphatase inhibitors (Roche). GISTs were isolated from three cKit V558D/+ male sibling mice at 12 weeks of age. 
Statistical analysis
Data were presented as the mean + SEM of at least three separate experiments if not indicated in the figures. One-way ANOVA was used for comparison among more than two groups. Student's t-test was used for comparison between two groups. Values of P , 0.05 were accepted as significant.
